96 related articles for article (PubMed ID: 18756880)
21. Long-term outcomes of visual field defects after indocyanine green-assisted macular hole surgery.
Yamashita T; Uemura A; Kita H; Nakao K; Sakamoto T
Retina; 2008 Oct; 28(9):1228-33. PubMed ID: 19430390
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of visual function among patients with exudative AMD treated with an intravitreal injection of triamcinolone acetonide].
Lubiński W; Gosławski W; Mozolewska-Piotrowska K; Szych Z; Karczewicz D
Ann Acad Med Stetin; 2008; 54(1):22-7; discussion 27. PubMed ID: 19127806
[TBL] [Abstract][Full Text] [Related]
23. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration.
Hayashi H; Yamashiro K; Tsujikawa A; Ota M; Otani A; Yoshimura N
Am J Ophthalmol; 2009 Jul; 148(1):83-9.e1. PubMed ID: 19327745
[TBL] [Abstract][Full Text] [Related]
24. Increased role of peripheral vision in self-induced motion in patients with age-related macular degeneration.
Tarita-Nistor L; González EG; Markowitz SN; Lillakas L; Steinbach MJ
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):3253-8. PubMed ID: 18390642
[TBL] [Abstract][Full Text] [Related]
25. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD.
Avila MP; Farah ME; Santos A; Kapran Z; Duprat JP; Woodward BW; Nau J
Retina; 2009 Feb; 29(2):157-69. PubMed ID: 19202425
[TBL] [Abstract][Full Text] [Related]
26. The use of intraocular corticosteroids.
Kiernan DF; Mieler WF
Expert Opin Pharmacother; 2009 Oct; 10(15):2511-25. PubMed ID: 19761356
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal triamcinolone acetonide preceding photodynamic therapy for exudative age-related macular degeneration.
Roth DB; Kulkarni KM; Walsman S; Modi A
Ophthalmic Surg Lasers Imaging; 2009; 40(5):467-71. PubMed ID: 19772270
[TBL] [Abstract][Full Text] [Related]
28. Autologous transplantation of retinal pigment epithelium-Bruch's membrane complex for hemorrhagic age-related macular degeneration.
Ma Z; Han L; Wang C; Dou H; Hu Y; Feng X; Xu Y; Wang Z; Yin Z; Liu Y
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2975-81. PubMed ID: 19117919
[TBL] [Abstract][Full Text] [Related]
29. A comparison of macular translocation with patch graft in neovascular age-related macular degeneration.
Chen FK; Patel PJ; Uppal GS; Rubin GS; Coffey PJ; Aylward GW; Da Cruz L
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1848-55. PubMed ID: 19060287
[TBL] [Abstract][Full Text] [Related]
30. Age related macular degeneration--should your patients be taking additional supplements?
Jones AA
Aust Fam Physician; 2007 Dec; 36(12):1026-8. PubMed ID: 18075628
[TBL] [Abstract][Full Text] [Related]
31. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
Keane PA; Chang KT; Liakopoulos S; Jivrajka RV; Walsh AC; Sadda SR
Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
[TBL] [Abstract][Full Text] [Related]
32. First versus second eye intravitreal ranibizumab therapy for wet AMD.
Eldaly MA; Styles C
Retina; 2009 Mar; 29(3):325-8. PubMed ID: 19287289
[TBL] [Abstract][Full Text] [Related]
33. Re: Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
Uparkar M; Bhende M
Retina; 2009; 29(10):1549; author reply 1549-50. PubMed ID: 19898197
[No Abstract] [Full Text] [Related]
34. The utility of using customized heterochromatic flicker photometry (cHFP) to measure macular pigment in patients with age-related macular degeneration.
Stringham JM; Hammond BR; Nolan JM; Wooten BR; Mammen A; Smollon W; Snodderly DM
Exp Eye Res; 2008 Nov; 87(5):445-53. PubMed ID: 18778703
[TBL] [Abstract][Full Text] [Related]
35. Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Landa G; Butovsky O; Shoshani J; Schwartz M; Pollack A
Curr Eye Res; 2008 Nov; 33(11):1011-3. PubMed ID: 19085384
[TBL] [Abstract][Full Text] [Related]
36. Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy.
Das R; Shi Y; Silvestri G; Chakravarthy U
Retina; 2009; 29(7):1013-8. PubMed ID: 19584658
[TBL] [Abstract][Full Text] [Related]
37. Epidemiological study of sun exposure and visual field damage in children in Primorsko-Goranska County--the risk factors of earlier development of macular degeneration.
Vojniković B; Synek S; Mićović V; Telezar M; Linsak Z
Coll Antropol; 2010 Apr; 34 Suppl 2():57-9. PubMed ID: 21302703
[TBL] [Abstract][Full Text] [Related]
38. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
Shah AR; Del Priore LV
Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
[TBL] [Abstract][Full Text] [Related]
39. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.
Theodossiadis PG; Liarakos VS; Sfikakis PP; Vergados IA; Theodossiadis GP
Am J Ophthalmol; 2009 May; 147(5):825-30, 830.e1. PubMed ID: 19211094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
